✦ LIBER ✦

Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: A study of the gynecologic oncology group

✍ Scribed by Gregory Sutton; John A. Blessing; Robert Park; Philip J. DiSaia; Neil Rosenshein

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dactinomycin in the Treatment of Recurre

✍ David H. Moore; John A. Blessing; Charles Dunton; Richard E. Buller; Gary C. Rei 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 33 KB

Late-Breaking Abstract 1: Randomized pha

✍ D. Miller; V. Filiaci; G. Fleming; R. Mannel; D. Cohn; T. Matsumoto; K. Tewari; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 108 KB

A phase II evaluation of aflibercept in

✍ Robert L. Coleman; Michael W. Sill; Heather A. Lankes; Amanda Nickles Fader; Nei 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 246 KB

A phase II study of gemcitabine (gemzar,

✍ David L. Tait; John A. Blessing; James S. Hoffman; Kathleen N. Moore; Nick M. Sp 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 151 KB

A Phase II Trial of Ifosfamide and Mesna

✍ Gregory P. Sutton; John A. Blessing; Howard D. Homesley; John H. Malfetano 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 165 KB

A phase II evaluation of weekly docetaxe

✍ Agustin A. Garcia; John A. Blessing; Susan Nolte; Robert S. Mannel 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 135 KB